Can people with type 1 diabetes take weight loss injections?

Are Mounjaro and Wegovy actually licensed for type 1 diabetes?

Neither Mounjaro (tirzepatide) nor Wegovy (semaglutide injection) holds a UK marketing authorisation that covers type 1 diabetes. Mounjaro's licence spans weight management in adults with a body mass index of 30 or above, or 27 and above alongside at least one weight-related condition, and the management of type 2 diabetes. Wegovy's weight-management licence has a similar BMI framework. Type 1 diabetes is an autoimmune condition with a fundamentally different mechanism from type 2, and the large phase 3 trials that underpinned both licences, including SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide, enrolled adults without type 1 diabetes.

You can read the full prescribing information for tirzepatide on NHS England's tirzepatide medicine page, which also summarises who the medicine is intended for. NICE's appraisal of tirzepatide (TA1026) likewise sets out the specific population the committee evaluated. None of that population includes people managing type 1 diabetes. That is not a judgement about whether such patients need support with weight; it reflects where the evidence base currently stands.

For people with type 2 diabetes, the situation is different. Weight loss injections and type 2 diabetes have a well-established evidence base, and both Mounjaro and Wegovy are licensed or recommended in relevant NICE guidance for that group. The distinction between type 1 and type 2 matters enormously here, so it is worth being precise about which condition is being discussed whenever you research this topic.

What makes type 1 diabetes a distinct safety consideration?

Even setting aside the licensing question, type 1 diabetes introduces safety variables that do not apply to the general weight-loss population. GLP-1 medicines slow the rate at which food leaves the stomach. In someone managing insulin doses precisely timed to meals, slower gastric emptying can make glucose patterns less predictable and increase the risk of hypoglycaemia, particularly if insulin doses are not adjusted downward to match a reduced appetite and altered digestion timeline.

The MHRA's published guidance for GLP-1 medicines flags gastrointestinal effects as the most common side effects: nausea, vomiting and diarrhoea occur frequently, especially at the start of treatment or after a dose increase. For most people this is uncomfortable but manageable. For someone on fixed or basal-bolus insulin, persistent nausea that reduces food intake without a corresponding insulin reduction can push blood glucose dangerously low. That is a meaningful clinical risk that requires specialist oversight, not a general weight-loss prescriber working from a remote consultation alone.

There is also the question of diabetic ketoacidosis. Any significant reduction in calorie intake or disruption to eating patterns in type 1 diabetes warrants careful monitoring. These are not reasons to say these medicines can never have a role, but they do mean the safety bar for type 1 diabetes is higher than for the general population, and the involvement of a diabetes care team is not optional. Our clinical team takes that threshold seriously.

Is there any research into GLP-1 medicines in type 1 diabetes?

There is, and it is worth knowing about even if the conclusions are not yet settled. A number of smaller trials and real-world studies have looked at GLP-1 receptor agonists in type 1 diabetes, with some showing modest weight reduction and improvements in glycaemic variability alongside lower insulin requirements. The results are not consistent enough to have translated into a licensed indication or NICE-approved pathway, and the hypoglycaemia signal has appeared in several studies, reinforcing the need for careful titration and monitoring.

Research into tirzepatide's dual GIP and GLP-1 mechanism in type 1 diabetes is at an earlier stage. Some researchers have suggested the GIP component may have a different effect on glucagon regulation compared with GLP-1 alone, but this remains an area of active investigation rather than settled evidence. The NHS inform Scotland guidance on diabetes and weight loss medication captures the current position clearly: these medicines are not routinely recommended outside their licensed indications. If your diabetes team considers an off-label trial appropriate for you, that decision should come with structured glucose monitoring and a clear plan for insulin adjustment. It is not something to arrange independently.

What can people with type 1 diabetes do about weight management?

Weight management is a legitimate health priority for many people living with type 1 diabetes, and the lack of a licensed GLP-1 option does not mean support is unavailable. Your diabetes team, which may include a consultant endocrinologist, specialist diabetes nurse or dietitian, is the right first point of contact. They can assess whether any medicine, including off-label options, is clinically appropriate and how it would sit alongside your insulin regimen. If you want to understand the specific considerations involved, our page covering weight loss injections for type 1 diabetes goes into more detail about how these medicines relate to that condition.

Some people with type 1 diabetes may be eligible for structured weight management programmes through the NHS. The general landscape of weight loss treatment options in the UK has broadened considerably in recent years, and our page on diabetic injection for weight loss explains how these treatments work and which groups they are currently intended for. For people without type 1 diabetes who do qualify for licensed GLP-1 treatment, weight loss injections for people without diabetes follow a more straightforward path through a private prescription service like ours, with a consultation reviewed the same day by a GPhC-registered prescriber. People with type 1 diabetes need more than that pathway offers on its own.

If you are unsure where you stand or want to understand the full range of options available to you, speaking to your GP or diabetes specialist is genuinely the best next step. Our page covering the types of weight loss injections available in the UK is a useful starting point for understanding how the different medicines compare, and our frequently asked questions page covers eligibility criteria in more detail for people who do not have type 1 diabetes and are considering a weight loss injection.